PRELON Tablet - Lomus Pharmaceuticals Pvt. Ltd.

PRELON Tablet
Dosage Forms/Composition
Tablet: Each tablet contains Prednisolone 5mg/10mg/20mg.
Pharmacological Index
Corticosteroid
INDICATION
Allergic and inflammatory conditions, bronchial asthma, severe dermatological
reactions, acute asthma, as anti-inflammatory or immunosuppressant, nephrotic
syndrome, rheumatoid arthritis, ulcerative colitis, crohn’s disease, psoriasis, systemic
lupus erythematosus.
Pregnancy Risk Factor
C
Contraindications
Acute superficial herpes simplex keratitis; systemic fungal infections; varicella;
hypersensitivity to prednisolone or any component.
Warnings/Precautions
Use with caution in patients with hyperthyroidism, cirrhosis, nonspecific ulcerative
colitis, hypertension, osteoporosis, thromboembolic tendencies, CHF, convulsive
disorders, myasthenia gravis, thrombophlebitis, peptic ulcer, diabetes; acute adrenal
insufficiency may occur with abrupt withdrawal after long-term therapy or with stress;
young pediatric patients may be more susceptible to adrenal axis suppression from
topical therapy. Because of the risk of adverse effects, systemic corticosteroids should
be used cautiously in the elderly, in the smallest possible dose, and for the shortest
possible time.
Adverse Reactions
>10%:
Central nervous system: Insomnia, nervousness
Gastrointestinal: Increased appetite, indigestion
1% to 10%:
Dermatologic: Hirsutism
Endocrine & metabolic: Diabetes mellitus
Neuromuscular & skeletal: Arthralgia
Ocular: Cataracts, glaucoma
Respiratory: Epistaxis

ulcerative esophagitis, pancreatitis, muscle weakness, osteoporosis, fractures, muscle
wasting, hypersensitivity reactions.
Overdosage/Toxicology
When consumed in excessive quantities for prolonged periods, systemic
hypercorticism and adrenal suppression may occur, in those cases discontinuation and
withdrawal of the corticosteroid should be done judiciously.
Drug Interactions
CYP3A enzyme substrate; inducer of cytochrome P-450 enzymes
Barbiturates, phenytoin, rifampin decrease corticosteroid effectiveness
Decreases salicylates
Decreases vaccines
Decreases toxoids effectiveness
Mechanism of Action
Decreases inflammation by suppression of migration of polymorphonuclear leukocytes
and reversal of increased capillary permeability; suppresses the immune system by
reducing activity and volume of the lymphatic system.
Pharmacodynamics/Kinetics
Duration: 18-36 hours
Protein binding: 65% to 91% (concentration dependent)
Metabolism: Primarily in the liver, but also metabolized in most tissues, to inactive
compounds
Half-life: 3.6 hours; Biological: 18-36 hours; End-stage renal disease: 3-5 hours
Elimination: In urine principally as glucuronides, sulfates, and unconjugated
metabolites.
Usual Dosage
The starting dose may be from 5-60mg per day and often is adjusted based on the
response of the condition being treated.
Patient Information
Take exactly as directed; do not increase dose or discontinue abruptly without
consulting prescriber. Take oral medication with or after meals. Limit intake of caffeine
or stimulants. Prescriber may recommend increased dietary vitamins, minerals, or iron.
Diabetics should monitor glucose levels closely (antidiabetic medication may need to
be adjusted). Inform prescriber if you are experiencing greater than normal levels of
stress (medication may need adjustment). Some forms of this medication may cause GI
upset (oral medication may be taken with meals to reduce GI upset; small frequent
meals and frequent mouth care may reduce GI upset). You may be more susceptible to
infection (avoid crowds and persons with contagious or infective conditions). Report
promptly excessive nervousness or sleep disturbances; any signs of infection (sore
throat, unhealed injuries); excessive growth of body hair or loss of skin color; changes
in vision; excessive or sudden weight gain (>3 lb/week); swelling of face or extremities;
difficulty breathing; muscle weakness; change in color of stools (black or tarry) or
persistent abdominal pain; or worsening of condition or failure to improve. Pregnancy

precautions: Inform prescriber if you are or intend to be pregnant.
LOMUS Drug Information Center
Lomus Pharmaceuticals Pvt. Ltd.
P.O. Box No 4506, Lomus House (Corporate office),
Kailash Chour, Lazimpat, Kathmandu, Nepal
Ph: 4436396 (Hunting Line). Fx: 977-1-4436395
E-mail: druginfo@lomus.com.np